Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: Evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers

A. T. Koki, N. K. Khan, B. M. Woerner, K. Seibert, J. L. Harmon, Andrew Dannenberg, R. A. Soslow, J. L. Masferrer

Research output: Contribution to journalArticle

46 Scopus citations

Abstract

Increased prostaglandins (PGs) are associated with many inflammatory pathophysiological conditions; and are synthesized from arachidonic acid by either of 2 enzymes, cyclooxygenase-1 (COX-1) or -2 (COX-2). Recent epidemiologic, expression, and pharmacologic studies suggest COX-2 derived metabolites also play a functional role in the maintenance of tumor viability, growth and metastasis. Archival and/or prospectively collected human tissues were prepared for immunohistochemistry, and representative cases assayed via Western blot, RT-PCR, or TAQman analysis. Consistent overexpression of COX-2 was observed in a broad range of premalignant, malignant, and metastatic human epithelial cancers. COX-2 was detected in ca. 85% of the hyperproliferating, dysplastic, and neoplastic epithelial cells, and in the existing and angiogenic vasculature within and adjacent to hyperplastic/neoplastic lesions. These data collectively imply COX-2 may play an important role during premalignant hyperproliferation, as well as the later stages of invasive carcinoma and metastasis in various human epithelial cancers.

Original languageEnglish (US)
Pages (from-to)13-18
Number of pages6
JournalProstaglandins Leukotrienes and Essential Fatty Acids
Volume66
Issue number1
DOIs
StatePublished - Jan 1 2002

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Cell Biology

Fingerprint Dive into the research topics of 'Characterization of cyclooxygenase-2 (COX-2) during tumorigenesis in human epithelial cancers: Evidence for potential clinical utility of COX-2 inhibitors in epithelial cancers'. Together they form a unique fingerprint.

Cite this